This article was originally published in The Gray Sheet
Acquisition of North American Vaccine announced Nov. 15 is valued at about $390 mil. The company has offered $7 per share, $6.97 in Baxter common stock and $0.03 cash for the 37 mil. shares of NAVA stock outstanding. Baxter also will assume $133 mil. in debt. In addition, BioChem Pharma has agreed to sell its 13.2-mil. share stake in NAVA to Baxter. Those shares are worth roughly $92 mil. under the deal, which brings NAVA's bacterial vaccine experience to Baxter's viral vaccine expertise. In addition, Baxter announces that CEO Harry Kraemer will assume the additional title of chairman following the retirement of Vernon Loucks on Dec. 31
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.